Isotechnika sells China rights to transplant drug voclosporin to 3SBio in China for $6 million

Chinese biotechnology firm 3SBio (Nasdaq: SSRX) and Canada's Isotechnika Pharma (TSX: ISA) have signed a development and commercialization agreement for the latter's voclosporin, a next generation calcineurin inhibitor being developed for use in the prevention of organ rejection following transplantation and the treatment of autoimmune diseases.

Under the terms of the accord, Isotechnika will grant 3SBio exclusive rights to all transplant and autoimmune indications of voclosporin in China, including Hong Kong and Taiwan, excluding ophthalmic indications and medical devices which were previously licensed to Lux Biosciences and Atrium Medical Corp, respectively. 3SBio will be responsible for the clinical development, registration and commercialization of voclosporin in China. Isotechnika will provide, under separate agreement, commercial supply to 3SBio on a cost-plus basis. Isotechnika will receive an upfront non-refundable licensing payment of $1.5 million as well as ongoing royalties based on sales of voclosporin by 3SBio.

$4.5 million investment in Isotechnika